475889 Sigma-AldrichMK-886 - CAS 118414-82-7 - Calbiochem
A cell-permeable, orally active NSAID that blocks cellular Cox pathway PGE2 production by inhibiting COX-1 and mPGES-1, but not COX-2, activity, as well as suppresses cellular 5-LO pathway activation by inhibiting FLAP, rather than 5-LO, activity.
More>> A cell-permeable, orally active NSAID that blocks cellular Cox pathway PGE2 production by inhibiting COX-1 and mPGES-1, but not COX-2, activity, as well as suppresses cellular 5-LO pathway activation by inhibiting FLAP, rather than 5-LO, activity. Less<<MK-886 - CAS 118414-82-7 - Calbiochem : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
Synonymes: 3-[1-(p-Chlorobenzyl)-5-(isopropyl)-3-t-butylthioindol-2-yl]-2,2-dimethylpropanoic Acid, Na, COX-1 Inhibitor III, FLAP Inhibitor I, MK886, mPGES-1 Inhibitor I
Produits recommandés
Aperçu
| Replacement Information |
|---|
Tableau de caractéristiques principal
| CAS # | Empirical Formula |
|---|---|
| 118414-82-7 | C₂₇H₃₃ClNO₂S · Na |
Products
| Référence | Conditionnement | Qté | |
|---|---|---|---|
| 475889-5MG | Ampoule plast. | 5 mg |
| Description | |
|---|---|
| Overview | A cell-permeable, orally active NSAID (nonsteroidal antiinflammatory drug) that blocks cellular Cox pathway PGE2 (prostaglandin E2) production by inhibiting COX-1 and mPGES-1 (microsomal PGE2 synthase-1), but not COX-2, activity (IC50 = 8, 2, and 58 µM, respectively), as well as suppresses cellular 5-LO (5-Lypoxygenase; Cat. No. 437996) pathway activation by inhibiting FLAP (5-LO-activating protein), rather than 5-LO, activity (<10% by 1 µM MK-886). Unlike NSAIDs (nonsteroidal antiinflammatory drugs) that target only COX pathway, MK-886 does not cause gastrointestinal damages when applied in vivo. |
| Catalogue Number | 475889 |
| Brand Family | Calbiochem® |
| Synonyms | 3-[1-(p-Chlorobenzyl)-5-(isopropyl)-3-t-butylthioindol-2-yl]-2,2-dimethylpropanoic Acid, Na, COX-1 Inhibitor III, FLAP Inhibitor I, MK886, mPGES-1 Inhibitor I |
| Product Information | |
|---|---|
| CAS number | 118414-82-7 |
| ATP Competitive | N |
| Form | White solid |
| Hill Formula | C₂₇H₃₃ClNO₂S · Na |
| Chemical formula | C₂₇H₃₃ClNO₂S · Na |
| Reversible | N |
| Structure formula Image | |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | leukotreine biosybthesis |
| Primary Target IC<sub>50</sub> | 102 nM |
| Purity | ≥99% by TLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | Y |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information |
|---|
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Référence | GTIN |
| 475889-5MG | 04055977203592 |
Documentation
MK-886 - CAS 118414-82-7 - Calbiochem FDS
| Titre |
|---|
MK-886 - CAS 118414-82-7 - Calbiochem Certificats d'analyse
| Titre | Numéro de lot |
|---|---|
| 475889 |
Références bibliographiques
| Aperçu de la référence bibliographique |
|---|
| Koeberle, A., et al. 2009. Eur. J. Pharmacol. 608, 84. Koeberle, A., et al. 2008. J. Pharmacol. Exp. Ther. 326, 975. Fisher, L., et al. 2007. Br. J. Pharmacol. 152, 471. Ford-Hutchinson, A.W., et al. 1993. Can. J. Physiol. Pharmacol. 71, 806. Ford-Hutchinson, A.W. 1991. Trends Pharmacol. 12, 68. Dixon, R.A., et al. 1990. Nature 343, 282. Rouzer, C.A., et al. 1990. J. Biol. Chem. 265, 1436. |
| Fiche technique | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
|